Study wrapper · #975
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
Carvas AO, Leuthardt A, Kulka P, et al. EBioMedicine. 2025.
DOI: 10.1016/j.ebiom.2025.105836PubMed: 40609154
Editor's note
A knockout-mouse study showing cagrilintide's body-weight effect requires amylin receptors 1 and 3, mapping its central mechanism to specific brainstem circuits. Findings are in mice and mechanistic, not clinical. Directly focused on a tracked peptide.
Plain-language abstract
In mice, cagrilintide's weight-lowering effect depended on brain amylin receptors 1 and 3.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Physiology & behaviorn=——2026
Supported
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacologyn=——2026